Thomas also commented on his company's other quarterly disappointment, its biomedical products division. He said that while Chart Industries anticipated consolidation in the industry, the pullback in demand was more than expected. Once that consolidation is completed, however, Thomas sees that business improving. In closing, Thomas said Chart remains a great growth story and will be a key supplier in a rapidly growing industry. However, it has been difficult to predict exactly when that will occur.